Drug Type Small molecule drug |
Synonyms Dinaciclib (USAN/INN), MK-7965, NSC-727135 + [5] |
Mechanism CDK1 inhibitors(Cyclin-dependent kinase 1 inhibitors), CDK2 inhibitors(Cyclin-dependent kinase 2 inhibitors), CDK5 inhibitors(Cyclin-dependent kinase 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC21H28N6O2 |
InChIKeyPIMQWRZWLQKKBJ-SFHVURJKSA-N |
CAS Registry779353-01-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09604 | Dinaciclib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic lymphocytic leukaemia refractory | Phase 3 | - | 01 Aug 2012 | |
Chronic Lymphocytic Leukemia | Phase 3 | IT | 20 Jun 2012 | |
B-Cell Prolymphocytic Leukemia | Phase 2 | US | 01 Jan 2012 | |
Small Lymphocytic Lymphoma | Phase 2 | US | 01 Jan 2012 | |
Acral Lentiginous Malignant Melanoma | Phase 2 | US | 01 Jul 2009 | |
Lentigo maligna melanoma | Phase 2 | US | 01 Jul 2009 | |
Malignant melanoma stage IV | Phase 2 | US | 01 Jul 2009 | |
Melanoma recurrent | Phase 2 | US | 01 Jul 2009 | |
Mucosal Melanoma | Phase 2 | US | 01 Jul 2009 | |
Plasma cell myeloma refractory | Phase 2 | US | 01 Jul 2009 |
Phase 1 | 39 | wrezxqvhew(nqsnphxqdv) = dinaciclib 9 mg/m2 and MK-2206 135 mg kvgfpwjwes (xknrulnubt ) View more | Negative | 01 Nov 2020 | |||
NCT01676753 (ASCO2020) Manual | Phase 1 | Triple Negative Breast Cancer HER2 Negative | ER Negative | PR Negative | 32 | aroltciwlt(dbvgashdfp) = The RP2D of dina given in combination with standard dose P is 33 mg/m2 yqvbojhrdu (tslpxfegki ) View more | Positive | 29 May 2020 | |
Phase 1 | 22 | mlcowbejpk(dmdfsjcbxg) = sgcgakpdgw nldhzhjvtb (samarautre ) View more | - | 26 May 2019 | |||
Phase 1/2 | 36 | eiamojhuis(oeckdjtgyf) = qqooltwfqh kkoczkexmq (diqjqhgnpv, rjtjkiwocu - emkukykknf) View more | - | 15 Mar 2018 | |||
Phase 1 | 61 | juuylcooiu(sapfcunmkx) = pancytopenia, neutropenic fever, elevated transaminases, hyperuricemia and hypotension ojextdfzzy (ouuqsobvgg ) View more | Positive | 24 Oct 2017 | |||
Phase 1 | - | rurzlsrcmd(wwjwvbnzct) = pymietvwaf bykphwrunr (pidnnzvrgz ) | - | 01 Jul 2017 | |||
Phase 1 | Triple Negative Breast Cancer triple negative | 9 | wsxmcglvih(vmxaiyozwq) = neutropenia (grade 3, n = 2), syncope (grade 3, n = 2) and vomiting (grade 3, n = 1) rmmxdpaifl (lwsuxuhfrv ) | Negative | 01 Aug 2015 | ||
Phase 1 | 52 | teguscbqvi(johvisdyks) = cytopenias, transient laboratory abnormalities and TLS kmekbhsjwd (wquyljqiqw ) | Positive | 01 Jul 2015 | |||
(14 mg/m2) | |||||||
Phase 2 | 27 | ctiaxmdozn(fdskoayuqb) = bduzdgnfmc emdfsddcfa (xulbdrzxzw ) View more | Positive | 15 Jan 2015 | |||
Phase 2 | Non-Small Cell Lung Cancer Third line | 97 | sczyrohkak(kogwrpldcv) = sqbnuxdyqg byapxjzfph (quywhywpfw ) | - | 01 Feb 2014 | ||
sczyrohkak(kogwrpldcv) = gjmsuhwhvr byapxjzfph (quywhywpfw ) |